CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Integra Lifesciences Holdings Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Integra Lifesciences Holdings Corp
1100 Campus Road
Phone: (609) 275-0500p:609 275-0500 PRINCETON, NJ  08540  United States Ticker: IARTIART

Business Summary
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Stuart M.Essig 62 2/27/2024 12/1/1997
President, Chief Executive Officer, Director JanDe Witte 60 12/1/2021 12/1/2021
Chief Financial Officer, Executive Vice President Lea D.Knight 52 6/28/2023 6/28/2023
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
LXU Healthcare, Inc. 3708 East Columbia Street Tucson AZ United States
Rebound Therapeutics Corporation 13900 Alton Parkway Irvine CA United States
Acclarent, Inc. 1525 Obrien Dr, Ste B MENLO PARK CA United States
11 additional Subsidiary records available in full report.

Business Names
Business Name
Acclarent, Inc.
ACell, Inc.
Arkis Biosciences Inc.
86 additional Business Names available in full report.

General Information
Number of Employees: 3,946 (As of 12/31/2023)
Outstanding Shares: 77,163,524 (As of 11/1/2024)
Shareholders: 749
Stock Exchange: NASD
Federal Tax Id: 510317849
Fax Number: (609) 750-4277


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024